Original article
Comparison of mitozantrone and epirubicin in advanced breast cancer

https://doi.org/10.1016/S0936-6555(96)80079-3Get rights and content

Abstract

Forty chemotherapy naive patients with metastatic or locally advanced breast cancer were treated in a randomized trial comparing mitozantrone 14 mg/m2 with epirubicin 75 mg/m2 given intravenously at 3-weekly intervals. There was a 40% (95% confidence interval (CI) 8–72; P = 0.013) higher partial response rate with epirubicin (11/18) than with mitozantrone (4/19). Epirubicin caused significantly more alopecia (difference 76%; 95% CI 57–96; P < 0.0001) and nausea/vomiting (difference = 38%; 95% CI 10–67; P = 0.01). Three patients who received long courses of epirubicin experienced cardiac failure; two were proved to have cardiomyopathy. The median survival for the epirubicin and mitozantrone groups were 9.5 and 8 months respectively. Thus, although epirubicin gave a higher response rate it also caused more toxicity.

References (15)

  • Stuart-HarrisR et al.

    Patient treatment preference in advanced breast cancer: A randomized cross-over study of doxorubicin and mitozantrone

    Eur J Cancer Clin Oncol

    (1987)
  • LawtonPA et al.

    A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast cancer

    Clin Oncol

    (1993)
  • AllegraJC et al.

    A randomized trial comparing mitozantrone with doxorubicin in patients with Stage IV breast cancer

    Invest New Drugs

    (1985)
  • HendersonIC et al.

    Randomized clinical trial comparing mitozantrone with doxorubicin in previously treated patients with metastatic breast cancer

    J Clin Oncol

    (1989)
  • NeidhartJA et al.

    A comparison of mitozantrone and doxorubicin in breast cancer

    J Clin Oncol

    (1986)
  • BennettJM et al.

    A randomized multicenter trial comparing mitozantrone, cyclophosphamide and fluorouracil with doxorubicin, cyclophosphamide and fluorouracil, in the therapy of metastatic breast carcinoma

    J Clin Oncol

    (1988)
  • PowlesTJ et al.

    Treatment of advanced breast cancer with Mitomycin-C, mitozantrone and methotrexate (3M) compared to vincristine, anthracycline and cyclophosphamide (VAC)

There are more references available in the full text version of this article.

Cited by (6)

View full text